Heparin and deep vein thrombosis
Phase 2
- Conditions
- Deep vein throbmosis.Formation of thrombosis in the deep veins
- Registration Number
- IRCT201402113449N14
- Lead Sponsor
- Vice Chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Critically ill patients with age between 18-65 years old who will be admitted to ICU and have indication for deep vein thrombosis (DVT) prophylaxis
Exclusion criteria:
Patients who need DVT or pulmonary emboli treatment, have heparin contraindications, autoimmune diseases, history of acute myocardial infarction in last 21 days, and dialysis.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of deep vein thrombosis. Timepoint: Daily up to 7 days. Method of measurement: Clinical assessment.
- Secondary Outcome Measures
Name Time Method Interleukin-10 serum level. Timepoint: Days 0,3,7. Method of measurement: Elisa kit.;P-selectin serum level. Timepoint: Days 0,3,7. Method of measurement: Elisa kit.;Hs-CRP serum level. Timepoint: Days 0,3,7. Method of measurement: Elisa kit.